A Phase Ib, Open Label, Multi-center Study to Characterize the Safety, Tolerability and Preliminary Efficacy of EGF816 in Combination With Selected Targeted Agents in EGFR Mutant NSCLC
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Nazartinib (Primary) ; Capmatinib; Gefitinib; Naporafenib; Ribociclib; Trametinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 01 Feb 2024 Planned End Date changed from 30 Sep 2024 to 16 Dec 2024.
- 01 Feb 2024 Planned primary completion date changed from 30 Sep 2024 to 16 Dec 2024.
- 17 Jul 2023 Planned End Date changed from 25 Mar 2024 to 30 Sep 2024.